View Filing Data

Balance Sheets - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 44,006,162	$ 30,182,115
Accounts receivable, net of allowance of $412,813 and $380,212 at 2020 and 2019, respectively	3,041,100	5,329,577
Inventories, net	4,576,078	1,847,530
Prepaid expenses and other current assets	1,611,504	1,470,922
Total current assets	53,234,844	38,830,144
Property and equipment, net	263,039	250,443
Operating lease right-of-use assets	3,282,783	4,286,064
Other assets	269,542	218,103
Total assets	57,050,208	43,584,754
Current liabilities:
Short-term debt	2,158,310
Accounts payable	1,571,679	2,099,097
Accrued liabilities	2,401,625	2,721,104
Deferred revenue	5,456,595	5,092,455
Current portion of operating lease liabilities	2,265,546	2,248,189
Total current liabilities	13,853,755	12,160,845
Long-term deferred revenue	508,772	554,258
Operating lease liabilities	1,069,090	2,089,537
Other liabilities	255,517	255,517
Total liabilities	15,687,134	15,060,157
Series A - Convertible preferred stock:
Convertible preferred stock, Series A, par value $0.001; 22,813 and 23,110 shares outstanding at 2020 and 2019, respectively	5,682,141	5,758,190
Stockholders’ equity:
Convertible preferred stock, Series B, par value $0.001; 10,000,000 shares authorized, 5,610,121 shares outstanding at 2020 and 2019	5,610	5,610
Common stock, par value $0.001; 300,000,000 shares authorized, 73,030,824 and 68,529,623 shares issued at 2020 and 2019, respectively	73,031	68,530
Additional paid in capital	521,013,702	504,211,040
Treasury stock, 4,015 shares at 2020 and 2019	(205,999)	(205,999)
Accumulated deficit	(485,205,411)	(481,312,774)
Total stockholders’ equity	35,680,933	22,766,407
Total liabilities and stockholders’ equity	$ 57,050,208	$ 43,584,754

Balance Sheets (Parenthetical) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Statement of Financial Position [Abstract]
Accounts receivable, allowance	$ 412,813	$ 380,212
Series A Convertible Preferred Stock, par value	$ 0.001	$ 0.001
Series A Convertible Preferred Stock, shares outstanding	22,813	23,110
Series B Convertible Preferred Stock, par value	$ 0.001	$ 0.001
Series B Convertible Preferred Stock, shares authorized	10,000,000	10,000,000
Series B Convertible Preferred Stock, shares outstanding	5,610,121	5,610,121
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	300,000,000	300,000,000
Common stock, shares issued	73,030,824	68,529,623
Treasury stock, shares	4,015	4,015

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
Statements of Operations (Unaudited) - USD ($)	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue:
Total revenue	$ 5,345,455	$ 6,798,111	$ 11,101,696	$ 13,807,985
Sublease	246,530	251,996	493,060	493,061
Cost of revenue:
Total cost of revenue	1,084,981	1,147,492	2,036,396	2,559,545
Sublease	246,530	246,531	493,060	493,061
Gross margin	4,260,474	5,650,619	9,065,300	11,248,440
Operating expenses:
Research and development	1,976,942	2,695,162	4,086,112	5,654,381
Sales and marketing	2,541,749	3,236,516	5,457,173	6,546,342
General and administrative	1,663,456	1,178,469	3,496,181	2,646,629
Total operating expenses	6,182,147	7,110,147	13,039,466	14,847,352
Operating loss	(1,921,673)	(1,459,528)	(3,974,166)	(3,598,912)
Interest income	567	31,810	81,529	48,374
Net loss	(1,921,106)	(1,427,718)	(3,892,637)	(3,550,538)
Cumulative dividend on convertible preferred stock	(342,126)	(357,194)	(685,849)	(710,704)
Loss attributable to common stockholders	$ (2,263,232)	$ (1,784,912)	$ (4,578,486)	$ (4,261,242)
Net loss per share attributable to common stockholders:
Basic	$ (0.03)	$ (0.03)	$ (0.06)	$ (0.07)
Diluted	$ (0.03)	$ (0.03)	$ (0.06)	$ (0.07)
Weighted average number of common shares and equivalents:
Basic	71,628,762	60,052,673	70,749,401	59,936,606
Diluted	71,628,762	60,052,673	70,749,401	59,936,606
Systems [Member]
Revenue:
Total revenue	$ 12,769	$ (0)	$ 12,769	$ 58,051
Cost of revenue:
Total cost of revenue	157,514	6,201	222,536	57,365
Disposables, Service and Accessories [Member]
Revenue:
Total revenue	5,086,156	6,546,115	10,595,867	13,256,873
Cost of revenue:
Total cost of revenue	$ 680,937	$ 894,760	$ 1,320,800	$ 2,009,119

Statements of Convertible Preferred Stock and Stockholders' Equity (Unaudited) - USD ($)	Convertible Preferred Stock Series A [Member]	Convertible Preferred Stock Series B [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2018	$ 5,960,475		$ 59,058	$ 478,179,574	$ (205,999)	$ (476,721,490)	$ 1,311,143
Beginning Balance, Shares at Dec. 31, 2018	23,900	(0)	59,058,297
Issuance of common stock and warrants			$ 47	(50,479)			(50,432)
Issuance of common stock and warrants, Shares			46,484
Share-based compensation			$ 174	954,808			954,982
Share-based compensation, shares			174,462
Components of net loss						$ (3,550,538)	(3,550,538)
Employee stock purchase plan			$ 24	$ 31,934			$ 31,958
Employee stock purchase plan, Shares			23,757
Issuance of common stock, Shares
Preferred stock conversion	$ (11,522)		$ 80	$ 11,442			$ 11,522
Preferred stock conversion, shares	(45)		80,038
Ending balance, value at Jun. 30, 2019	$ 5,948,953		$ 59,383	479,127,279	(205,999)	$ (480,272,028)	(1,291,365)
Ending Balance, Shares at Jun. 30, 2019	23,855	(0)	59,383,038
Beginning balance, value at Mar. 31, 2019	$ 5,955,354		$ 59,308	478,363,886	(205,999)	(478,844,310)	(627,115)
Beginning Balance, Shares at Mar. 31, 2019	23,880		59,308,237
Issuance of common stock and warrants			$ 14	(66,869)			(66,855)
Issuance of common stock and warrants, Shares			13,397
Share-based compensation			$ 7	807,021			807,028
Share-based compensation, shares			7,500
Components of net loss						(1,427,718)	(1,427,718)
Employee stock purchase plan			$ 9	16,885			16,894
Employee stock purchase plan, Shares			9,132
Issuance of common stock
Issuance of common stock, Shares
Preferred stock conversion	$ (6,401)		$ 45	6,356			6,401
Preferred stock conversion, shares	(25)		44,772
Ending balance, value at Jun. 30, 2019	$ 5,948,953		$ 59,383	479,127,279	(205,999)	(480,272,028)	(1,291,365)
Ending Balance, Shares at Jun. 30, 2019	23,855	(0)	59,383,038
Beginning balance, value at Dec. 31, 2019	$ 5,758,190	$ 5,610	$ 68,530	504,211,040	$ (205,999)	(481,312,774)	22,766,407
Beginning Balance, Shares at Dec. 31, 2019	23,110	5,610,121	68,529,623
Issuance of common stock and warrants			$ 3,815	15,004,554			15,008,369
Issuance of common stock and warrants, Shares			3,815,092
Share-based compensation			$ 117	1,657,604			1,657,721
Share-based compensation, shares			116,989
Components of net loss						$ (3,892,637)	(3,892,637)
Employee stock purchase plan			$ 18	$ 65,006			$ 65,024
Employee stock purchase plan, Shares			17,835
Issuance of common stock, Shares
Preferred stock conversion	$ (76,049)		$ 551	$ 75,498			$ 76,049
Preferred stock conversion, shares	(297)		551,285
Ending balance, value at Jun. 30, 2020	$ 5,682,141	$ 5,610	$ 73,031	521,013,702	(205,999)	$ (485,205,411)	35,680,933
Ending Balance, Shares at Jun. 30, 2020	22,813	5,610,121	73,030,824
Beginning balance, value at Mar. 31, 2020	$ 5,709,027	$ 5,610	$ 69,041	504,990,377	(205,999)	(483,284,305)	21,574,724
Beginning Balance, Shares at Mar. 31, 2020	22,918	5,610,121	69,040,781
Share-based compensation			$ 8	935,401			935,409
Share-based compensation, shares			7,500
Components of net loss						(1,921,106)	(1,921,106)
Employee stock purchase plan			$ 11	32,790			32,801
Employee stock purchase plan, Shares			11,429
Issuance of common stock			$ 3,774	15,028,445			15,032,219
Issuance of common stock, Shares			3,774,276
Preferred stock conversion	$ (26,886)		$ 197	26,689			26,886
Preferred stock conversion, shares	(105)		196,838
Ending balance, value at Jun. 30, 2020	$ 5,682,141	$ 5,610	$ 73,031	$ 521,013,702	$ (205,999)	$ (485,205,411)	$ 35,680,933
Ending Balance, Shares at Jun. 30, 2020	22,813	5,610,121	73,030,824

Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Jun. 30, 2020	Jun. 30, 2019
Cash flows from operating activities
Net loss	$ (3,892,637)	$ (3,550,538)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	58,300	56,032
Non-cash lease expense	1,171,170	1,171,171
Share-based compensation	1,657,721	473,093
Changes in operating assets and liabilities:
Accounts receivable	2,288,477	23,963
Inventories	(2,728,548)	(368,450)
Prepaid expenses and other current assets	(140,582)	449,292
Other assets	(51,439)	30,212
Accounts payable	(527,418)	(84,311)
Accrued liabilities	(319,479)	215,436
Deferred revenue	318,654	814,073
Operating lease liability	(1,170,979)	(1,145,340)
Other liabilities		(380,514)
Net cash used in operating activities	(3,336,760)	(2,295,881)
Cash flows from investing activities
Purchase of equipment	(70,896)	(9,833)
Net cash used in investing activities	(70,896)	(9,833)
Cash flows from financing activities
Proceeds from Paycheck Protection Program loan	2,158,310
Proceeds from issuance of stock, net of issuance costs	15,073,393	(18,444)
Net cash provided by (used in) financing activities	17,231,703	(18,444)
Net increase (decrease) in cash and cash equivalents	13,824,047	(2,324,158)
Cash and cash equivalents at beginning of period	30,182,115	10,796,072
Cash and cash equivalents at end of period	$ 44,006,162	$ 8,471,914

Description of Business

6 Months Ended

Jun. 30, 2020

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Description of Business

1. Description of Business

Stereotaxis designs, manufactures and markets an advanced robotic magnetic navigation system for use in a hospital’s interventional surgical suite, or “interventional lab”, that we believe revolutionizes the treatment of arrhythmias by enabling enhanced safety, efficiency, and efficacy for catheter-based, or interventional, procedures. Our primary products include the Genesis RMN System, the Niobe System, the Odyssey Solution, and related devices. We also offer to our customers the Stereotaxis Imaging Model S x-ray System.

The Genesis RMN and Niobe Systems are designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. This is achieved using externally applied magnetic fields that govern the motion of the working tip of the catheter, resulting in improved navigation, efficient procedures, and reduced x-ray exposure. As of June 30, 2020, the Company had an installed base of 123 Niobe ES Systems.

In addition to the robotic magnetic navigation systems and their components, Stereotaxis also has developed the Odyssey Solution, which consolidates lab information enabling physicians to focus on the patient for optimal procedure efficiency. The system also features a remote viewing and recording capability called Odyssey Cinema, which is an innovative solution that delivers synchronized content for optimized workflow, advanced care, and improved productivity. This tool includes an archiving capability that allows clinicians to store and replay entire procedures or segments of procedures. This information can be accessed from locations throughout the hospital local area network and over the global Odyssey Network providing physicians with a tool for clinical collaboration, remote consultation, and training.

We promote our full suite of products in a typical hospital implementation, subject to regulatory approvals or clearances. This implementation requires a hospital to agree to an upfront capital payment and recurring payments. The upfront capital payment typically includes equipment and installation charges. The recurring payments typically include disposable costs for each procedure, equipment service costs beyond warranty period, and ongoing software updates. In hospitals where our full suite of products has not been implemented, equipment upgrade or expansion can be implemented upon purchasing of the necessary upgrade or expansion.

We have received regulatory clearance, licensing and/or CE Mark approvals necessary for us to market the Genesis RMN System in the U.S. and Europe, and we are in the process of obtaining necessary registrations for extending our markets in other countries. The Niobe System, Odyssey Solution, Cardiodrive, and various disposable interventional devices have received regulatory clearance in the U.S., Europe, Canada, China, Japan and various other countries. We have received the regulatory clearance, licensing and/or CE Mark approvals that allow us to market the Vdrive and Vdrive Duo Systems with the V-CAS, V-Loop and V-Sono devices in the U.S., Canada and Europe. The V-CAS Deflect catheter advancement system has been CE Marked for sale in the Europe. Stereotaxis Imaging Model S is CE marked and FDA cleared.

We have strategic relationships with technology leaders and innovators in the global interventional market. Through these strategic relationships we provide compatibility between our robotic magnetic navigation system and digital imaging and 3D catheter location sensing technology, as well as disposable interventional devices. The maintenance of these strategic relationships, or the establishment of equivalent alternatives, is critical to our commercialization efforts. There are no guarantees that any existing strategic relationships will continue and efforts are ongoing to ensure the availability of integrated next generation systems and/or equivalent alternatives. We cannot provide assurance as to the timeline of the ongoing availability of such compatible systems or our ability to obtain equivalent alternatives on competitive terms or at all.

Summary of Significant Accounting Policies

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Basis of Presentation

The accompanying unaudited financial statements of Stereotaxis, Inc. have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and the instructions to Form 10-Q. Accordingly, they do not include all the disclosures required by GAAP for complete financial statements. In the opinion of management, they include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the results for the interim periods presented. Operating results for the six month period ended June 30, 2020 are not necessarily indicative of the results that may be expected for the year ending December 31, 2020 or for future operating periods.

These interim financial statements and the related notes should be read in conjunction with the annual financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 as filed with the Securities and Exchange Commission (SEC) on March 16, 2020.

Risks and Uncertainties

The novel coronavirus COVID-19 (“COVID-19”) pandemic has resulted, and is likely to continue to result, in significant disruptions to the economy, as well as business and capital markets around the world. The full extent of the impact of the COVID-19 pandemic on our business, results of operations and financial condition will depend on numerous evolving factors that we may not be able to accurately predict.

As a result of the COVID-19 outbreak, we have experienced business disruptions, including travel restrictions on us and our third-party distributors, which have negatively affected our complex sales, marketing, installation, distribution and service network relating to our products and services. The COVID-19 pandemic may continue to negatively affect demand for both our systems and our disposable products by limiting the ability of our sales personnel to maintain their customary contacts with customers as governmental authorities institute prolonged quarantines, travel restrictions, and shelter-in-place orders, or as our customers impose limitations on contacts and in-person meetings that go beyond those imposed by governmental authorities.

In addition, many of our hospital customers, for whom the purchase of our system involves a significant capital purchase which may be part of a larger construction project at the customer site (typically the construction of a new building), may themselves be under economic pressures. This may cause delays or cancellations of current purchase orders and other commitments, and may exacerbate the long and variable sales and installation cycles for our robotic systems products. We may also experience significant reductions in demand for our disposable products as our healthcare customers (physicians and hospitals) continue to re-prioritize the treatment of patients and divert resources away from non-coronavirus areas, which we anticipate will lead to the performance of fewer procedures in which our disposable products are used. In addition, patients may consider foregoing or deferring procedures utilizing our products, even if physicians and hospitals are willing to perform them, which could also reduce demand for, and sales of, our disposable products.

As of the date of the filing of this Quarterly Report on Form 10-Q, we believe our manufacturing operations and supply chains have been minimally interrupted, but we cannot guarantee that they will not be interrupted more severely in the future. If our manufacturing operations or supply chains are materially interrupted, it may not be possible for us to timely manufacture relevant products at required levels, or at all. A material reduction or interruption to any of our manufacturing processes would have a material adverse effect on our business, operating results, and financial condition.

As governmental authorities around the world continue to institute prolonged mandatory closures, social distancing protocols and shelter-in-place orders, or as private parties on whom we rely to operate our business put in place their own protocols that go beyond those instituted by relevant governmental authorities, our ability to adequately staff and maintain our operations or further our product development could be negatively impacted.

Any continued disruption to the capital markets could negatively impact our ability to raise capital. If the capital markets continue to be disrupted for an extended period of time and we need to raise additional capital, such capital may not be available on acceptable terms, or at all. Continued disruptions to the capital markets and other financing sources could also negatively impact our hospital customers’ ability to raise capital or otherwise obtain financing to fund their operations and capital projects. Such could result in delayed spending on current projects, a longer sales cycle for new projects where a large capital commitment is required, and decreased demand for our disposable products as well as an increased risk of customer defaults or delays in payments for our systems installation, service contracts and disposable products.

We continue to evaluate and take actions to reduce costs and spending across our organization. We will continue to actively monitor the situation and may take further actions that alter our business operations as may be required by federal, state, or local governmental authorities that may be implemented by our vendors, supplier or customers, or that we determine are in the best interests of our employees, customers, suppliers and shareholders.

Financial Instruments

Financial instruments consist of cash and cash equivalents, accounts receivable, accounts payable, and debt. The carrying value of such amounts reported at the applicable balance sheet dates approximates fair value.

The Company measures certain financial assets and liabilities at fair value on a recurring basis. General accounting principles for fair value measurement established a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets and liabilities (“Level 1”) and the lowest priority to unobservable inputs (“Level 3”). As of June 30, 2020 and December 31, 2019, the Company did not have any financial assets or liabilities valued at fair value on a recurring basis.

Revenue and Costs of Revenue

The Company accounts for revenue in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue from Contracts with Customers.

We generate revenue from initial capital sales of systems as well as recurring revenue from the sale of our proprietary disposable devices, from royalties paid to the Company on the sale by Biosense Webster of co-developed catheters, and from other recurring revenue including ongoing software updates and service contracts.

We account for a contract with a customer when there is a legally enforceable contract between the Company and the customer, the rights of the parties are identified, the contract has commercial substance, and collectability of the contract consideration is probable. We record our revenue based on consideration specified in the contract with each customer, net of any taxes collected from customers that are remitted to government authorities.

For contracts containing multiple products and services, the Company accounts for individual products and services as separate performance obligations if they are distinct, which is if a product or service is separately identifiable from other items in the bundled package, and if a customer can benefit from it on its own or with other resources that are readily available to the customer. The Company recognizes revenues as the performance obligations are satisfied by transferring control of the product or service to a customer.

For arrangements with multiple performance obligations, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services and market conditions. The Company regularly reviews standalone selling prices and updates these estimates as necessary.

Systems:

Contracts related to the sale of systems typically contain separate obligations for the delivery of system(s), installation and an implied obligation to provide software enhancements if and when available for one year following installation. Revenue is recognized when the Company transfers control to the customer, which is generally at the point when acceptance occurs that indicates customer acknowledgment of delivery or installation, depending on the terms of the arrangement. Revenue from the implied obligation to deliver software enhancements if and when available is recognized ratably over the first year following installation of the system as the customer receives the right to software updates throughout the period and is included in Other Recurring Revenue. The Company’s system contracts generally do not provide a right of return. Systems are generally covered by a one-year assurance type warranty; warranty costs were not material for the periods presented. Revenue from systems delivery and installation represented less than 1% for the six months ended June 30, 2020 and 2019.

Disposables:

Revenue from sales of disposable products is recognized when control is transferred to the customers, which generally occurs at the time of shipment, but can also occur at the time of delivery depending on the customer arrangement. Disposable products are covered by an assurance type warranty that provides for the return of defective products. Warranty costs were not material for the periods presented. Disposable revenue represented 31% and 36% of revenue for the six months ended June 30, 2020 and 2019, respectively.

Royalty:

The Company is entitled to royalty payments from Biosense Webster, payable quarterly based on net revenues from sales of the co-developed catheters. Royalty revenue from the co-developed catheters represented 9% and 10% of revenue for the six months ended June 30, 2020 and 2019, respectively.

Other Recurring Revenue:

Other recurring revenue includes revenue from product maintenance plans, other post warranty maintenance, and the implied obligation to provide software enhancements if and when available for one year following installation. Revenue from services and software enhancements is deferred and amortized over the service or update period, which is typically one year. Revenue related to services performed on a time-and-materials basis is recognized when performed. Other recurring revenue represented 56% and 50% of revenue for the six months ended June 30, 2020 and 2019, respectively.

Sublease Revenue:

The adoption of new lease accounting guidance as of January 1, 2019 required the Company to record sublease income as revenue beginning in 2019. Sublease revenue represented 4% of revenue for the six months ended June 30, 2020 and 2019.

	Three Months Ended June 30				Six Months Ended June 30,
	2020		2019		2020		2019
Systems	$	12,769	$	-	$	12,769	$	58,051
Disposables, service and accessories		5,086,156		6,546,115		10,595,867		13,256,873
Sublease		246,530		251,996		493,060		493,061
Total revenue	$	5,345,455	$	6,798,111	$	11,101,696	$	13,807,985

Transaction price allocated to remaining performance obligations relates to amounts allocated to products and services for which the revenue has not yet been recognized. A significant portion of this amount relates to the Company’s systems contracts and obligations that will be recognized as revenue in future periods. These obligations are generally satisfied within two years after contract inception but may occasionally extend longer. Transaction price representing revenue to be earned on remaining performance obligations on system contracts was approximately $4.2 million as of June 30, 2020. Performance obligations arising from contracts for disposables, royalty and service are generally expected to be satisfied within one year after entering into the contract.

The following information summarizes the Company’s contract assets and liabilities:

	June 30, 2020			December 31, 2019
Contract Assets - Unbilled Receivables	$	244,304		$	168,445

Customer deposits		597,000			-
Product shipped, revenue deferred		645,200			674,324
Deferred service and license fees		4,723,167			4,972,389
Total deferred revenue		5,965,367			5,646,713
Less: Long-term deferred revenue		(508,772	)		(554,258	)
Total current deferred revenue	$	5,456,595		$	5,092,455

The Company invoices its customers based on the billing schedules in its sales arrangements. Contract assets primarily represent the difference between the revenue that was earned but not billed on service contracts and revenue from system contracts that was recognized based on the relative selling price of the related performance obligations and the contractual billing terms in the arrangements. Deferred revenue is primarily related to service contracts, for which the service fees are billed up-front, generally quarterly or annually, and for amounts billed in advance for system contracts for which some performance obligations remain outstanding. For service contracts, the associated deferred revenue is generally recognized ratably over the service period. For system contracts, the associated deferred revenue is recognized when the remaining performance obligations are satisfied. The Company did not have any impairment losses on its contract assets for the periods presented.

Revenue recognized for the six months ended June 30, 2020 and 2019, that was included in the deferred revenue balance at the beginning of each reporting period was $4.0 million and $4.3 million respectively.

Assets Recognized from the Costs to Obtain a Contract with a Customer

The Company has determined that sales incentive programs for the Company’s sales team meet the requirements to be capitalized as the Company expects to generate future economic benefits from the related revenue generating contracts after the initial capital sales transaction. The costs capitalized as contract acquisition costs included in prepaid expenses and other assets in the Company’s balance sheet were $0.3 million as of June 30, 2020 and December 31, 2019. The Company did not incur any impairment losses during any of the periods presented.

Costs of systems revenue include direct product costs, installation labor and other costs, estimated warranty costs, and initial training and product maintenance costs. These costs are recorded at the time of sale. Costs of disposable revenue include direct product costs and estimated warranty costs and are recorded at the time of sale. Cost of revenue from services and license fees are recorded when incurred.

Share-Based Compensation

The Company accounts for its grants of stock options, stock appreciation rights, restricted shares, and restricted stock units and for its employee stock purchase plan in accordance with the provisions of general accounting principles for share-based payments. These accounting principles require the determination of the fair value of the share-based compensation at the grant date and the recognition of the related expense over the period in which the share-based compensation vests.

The Company utilizes the Black-Scholes valuation model to determine the fair value of stock options and stock appreciation rights at the date of grant. The resulting compensation expense is recognized over the requisite service period, which is generally four years. Restricted shares and units granted to employees are valued at the fair market value at the date of grant. The Company amortizes the fair market value to expense over the service period. If the shares are subject to performance objectives, the resulting compensation expense is amortized over the anticipated vesting period and is subject to adjustment based on the actual achievement of objectives.

Net Earnings (Loss) per Common Share

Basic earnings (loss) per common share is computed by dividing the net earnings (loss) for the period by the weighted average number of common shares outstanding during the period. In periods where there is net income, we apply the two-class method to calculate basic and diluted net income (loss) per share of common stock, as our Convertible Preferred Stock is a participating security. The two-class method is an earnings allocation formula that treats a participating security as having rights to earnings that otherwise would have been available to common stockholders. In periods where there is a net loss, the two-class method of computing earnings per share does not apply as our Convertible Preferred Stock does not contractually participate in our losses. We compute diluted net income (loss) per common share using net income (loss) as the “control number” in determining whether potential common shares are dilutive, after giving consideration to all potentially dilutive common shares, including stock options, warrants, unvested restricted stock units outstanding during the period and potential issuance of stock upon the conversion of our Convertible Preferred Stock issued and outstanding during the period, except where the effect of such securities would be antidilutive.

The following table sets forth the computation of basic and diluted EPS:

	2020			2019			2020			2019
	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Net loss	$	(1,921,106	)	$	(1,427,718	)	$	(3,892,637	)	$	(3,550,538	)
Cumulative dividend on convertible preferred stock		(342,126	)		(357,194	)		(685,849	)		(710,704	)
Net loss attributable to common stockholders	$	(2,263,232	)	$	(1,784,912	)	$	(4,578,486	)	$	(4,261,242	)

Weighted average number of common shares and equivalents:		71,628,762			60,052,673			70,749,401			59,936,606
Basic EPS	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.07	)
Diluted EPS	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.07	)

The Company did not include any portion of unearned restricted shares, outstanding options, stock appreciation rights, warrants or convertible preferred stock in the calculation of diluted loss per common share because all such securities are anti-dilutive for all periods presented. The application of the two-class method of computing earnings per share under general accounting principles for participating securities is not applicable during these periods because those securities do not contractually participate in its losses.

As of June 30, 2020, the Company had 2,536,900 shares of common stock issuable upon the exercise of outstanding options and stock appreciation rights at a weighted average exercise price of $2.87 per share, 15,385 shares of common stock issuable upon the exercise of outstanding warrants at a weighted average exercise price of $0.70 per share, 43,000,941 shares of common stock issuable upon the conversion of Series A Convertible Preferred Stock and accumulated dividends, 5,610,121 shares of common stock issuable upon the conversion of Series B Convertible Preferred Stock, and 933,473 shares of unvested restricted share units.

Recently Issued Accounting Pronouncements

In December 2019, the FASB issued ASU 2019-12, “Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes” as part of its effort to reduce the complexity of accounting standards. The ASU is effective for fiscal years beginning after December 15, 2020. The Company does not expect that the adoption of this new guidance will have a material impact on the Company’s financial results.

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments-Credit Losses (Topic 326), Measurement of Credit Losses on Financial Instruments” and also issued subsequent amendments to the initial guidance under ASU 2018-19, ASU 2019-04 and ASU 2019-05. The standard modifies the measurement approach for credit losses on financial instruments, including trade receivables, from an incurred loss method to a current expected credit loss method, otherwise known as “CECL.” The standard requires the measurement of expected credit losses to be based on relevant information, including historical experience, current conditions and a forecast that is supportable. The standard is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years; early adoption is permitted. The standard must be adopted by applying a cumulative adjustment to retained earnings. The Company anticipates adopting the standard in the first quarter of 2023, although it does not expect a significant impact to the Company’s financial results.

Inventories

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Inventories

3. Inventories

Schedule of Inventories

Inventories consist of the following:

	June 30, 2020			December 31, 2019
Raw materials	$	4,938,417		$	3,063,532
Work in process		563,838			515,262
Finished goods		2,988,008			2,164,187
Reserve for obsolescence		(3,914,185	)		(3,895,451	)
Total inventory	$	4,576,078		$	1,847,530

Prepaid Expenses and Other Assets

6 Months Ended

Jun. 30, 2020

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Prepaid Expenses and Other Assets

4. Prepaid Expenses and Other Assets

Prepaid expenses and other assets consist of the following:

	June 30, 2020			December 31, 2019
Prepaid expenses	$	831,103		$	640,252
Prepaid commissions		294,518			336,594
Deposits		665,308			712,179
Other assets		90,117			-
Total prepaid expenses and other assets		1,881,046			1,689,025
Less: Noncurrent prepaid expenses and other assets		(269,542	)		(218,103	)
Total current prepaid expenses and other assets	$	1,611,504		$	1,470,922

Property and Equipment

6 Months Ended

Jun. 30, 2020

Property, Plant and Equipment [Abstract]

Property and Equipment

5. Property and Equipment

Schedule of Property and Equipment

	June 30, 2020			December 31, 2019
Equipment	$	6,556,769		$	6,485,873
Leasehold improvements		2,338,441			2,338,441
		8,895,210			8,824,314
Less: Accumulated depreciation		(8,632,171	)		(8,573,871	)
Net property and equipment	$	263,039		$	250,443

Leases

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Leases

6. Leases

A lease is defined as a contract, or part of a contract, that conveys the right to control the use of identified property, plant or equipment for a period of time in exchange for consideration. On January 1, 2019, the Company adopted ASU No. 2016-02 “Leases” (Topic 842) and all subsequent ASUs that modified Topic 842. The Company determines if an arrangement contains a lease at inception. For the Company, Accounting Standards Codification (“ASC 842”) primarily affected the accounting treatment for operating lease agreements in which the Company is the lessee.

The Company leases its facilities under operating leases, which were previously not recognized on the Company’s balance sheets. With the adoption of ASC 842, operating lease agreements are required to be recognized on the balance sheet as a right-of-use (“ROU”) asset and a corresponding lease liability. These leases do not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. Further, the leases do not contain contingent rent provisions. Many of our leases include both lease (i.e., fixed payments including rent, taxes, and insurance costs) and non-lease components (i.e., common-area or other maintenance costs) which are accounted for as a single lease component as we have elected the practical expedient to group lease and non-lease components for all leases. A portion of our principal executive office is subleased to a third party through 2021. The sublease does not have significant rent escalation holidays, concessions, leasehold improvement incentives, or other build-out clauses. In addition, the sublease does not contain contingent rent provisions nor are there options to extend or terminate the sublease.

The Company’s lease agreements often include one or more options to renew at the Company’s discretion. If at lease inception, the Company considers the exercising of a renewal option to be reasonably certain, the Company will include the extended term in the calculation of the ROU asset and lease liability. The Company elected not to include short-term leases (i.e. leases with initial terms of twelve months or less) on the balance sheet.

The calculated amounts of the ROU assets and lease liabilities are impacted by the length of the lease term and the discount rate used to calculate the present value of the minimum lease payments. ASC 842 requires the use of the discount rate implicit in the lease whenever this rate is readily determinable. As this rate is rarely determinable, the Company utilizes its incremental borrowing rate at lease inception. At June 30, 2020, the weighted average discount rate for operating leases was 9.0% and the weighted average remaining lease term for operating lease term is 1.5 years.

The following table represents lease costs and other lease information.

	2020			2019			2020			2019
	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Operating lease cost	$	585,584		$	585,585		$	1,171,170		$	1,171,171
Short-term lease cost		19,304			18,831			34,774			38,639
Sublease income		(246,530	)		(251,996	)		(493,060	)		(493,061	)
Total lease cost	$	358,358		$	352,420		$	712,884		$	716,749

Cash paid within operating cash flows	$	588,897		$	612,224		$	1,225,247		$	1,227,490

The initial recognition of the right of use assets in 2019 was $6.2 million. Variable lease costs consist primarily of taxes, insurance, and common area or other maintenance costs for our leased facilities and equipment which are paid based on actual costs incurred.

Future minimum payments for operating leases with initial or remaining terms of one year or more as of June 30, 2020, excluding sublease income, were as follows:

	June 30, 2020
2020	$	1,168,947
2021		2,382,661
Total lease payments		3,551,608
Less: Interest		(216,972	)
Present value of lease liabilities	$	3,334,636

The undiscounted future cash flows to be received under the sublease are $0.5 million in 2020 and $1.0 million in 2021.

Accrued Liabilities

6 Months Ended

Jun. 30, 2020

Payables and Accruals [Abstract]

Accrued Liabilities

7. Accrued Liabilities

Accrued liabilities consist of the following:

Schedule of Accrued Liabilities

	June 30, 2020			December 31, 2019
Accrued salaries, bonus, and benefits	$	1,311,427		$	1,421,150
Accrued licenses and maintenance fees		483,879			483,879
Accrued warranties		127,705			141,697
Accrued taxes		200,041			206,232
Accrued professional services		206,903			383,342
Other		327,187			340,321
Total accrued liabilities		2,657,142			2,976,621
Less: Long term accrued liabilities		(255,517	)		(255,517	)
Total current accrued liabilities	$	2,401,625		$	2,721,104

Debt and Credit Facilities

6 Months Ended

Jun. 30, 2020

Debt Disclosure [Abstract]

Debt and Credit Facilities

8. Debt and Credit Facilities

The Company had a working capital line of credit with its primary lender, Silicon Valley Bank that matured on June 30, 2020.

The Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted on March 27, 2020 in the United States. Among the provisions contained in the CARES Act is the creation of the Paycheck Protection Program that provides for Small Business Administration (“SBA”) Section 7(a) loans for qualified small businesses. The loan can be forgiven as long as the funds are used for payroll related expenses as well as rent and utilities paid during the twenty four week period from the date of the loan along with maintaining certain headcount levels. On April 10, 2020, the Company was informed by its lender, Midwest BankCentre (the “Bank”), that the Bank received approval from the SBA to fund the Company’s request for a loan under the SBA’s Paycheck Protection Program (“PPP Loan”). Per the terms of the PPP Loan, the Company received total proceeds of $2,158,310 from the Bank on April 20, 2020. In accordance with the loan forgiveness requirements of the CARES Act, the Company intends to use the proceeds from the PPP Loan primarily for payroll costs, rent and utilities. The Company anticipates that the loan will be substantially forgiven. To the extent it is not forgiven, the Company would be required to repay that portion at an interest rate of 1% per annum, beginning November 2020 with a final installment in April 2022.

In accordance with general accounting principles for fair value measurement, the Company’s debt was measured at fair value (Level 2) as of June 30, 2020. As of June 30, 2020 the fair value of the debt approximated the carrying value of the debt.

Convertible Preferred Stock and Stockholders’ Equity

6 Months Ended

Jun. 30, 2020

Equity [Abstract]

Convertible Preferred Stock and Stockholders’ Equity

9. Convertible Preferred Stock and Stockholders’ Equity

The holders of common stock are entitled to one vote for each share held and to receive dividends whenever funds are legally available and when declared by the Board of Directors subject to the rights of holders of all classes of stock having priority rights as dividends and the conditions of the revolving line of credit agreement. No dividends have been declared or paid as of June 30, 2020.

2020 Equity Financing

On May 25, 2020, the Company entered into a Securities Purchase Agreement with certain accredited investors, whereby it, in a direct registered offering, agreed to issue and sell to the investors an aggregate of 3,658,537 shares of the Company’s common stock, $0.001 par value per share, at a price of $4.10 per share. The Company received net proceeds of approximately $15.0 million, after offering expenses.

2019 Equity Financing and Series B Convertible Preferred Stock

On August 7, 2019, the Company entered into a Securities Purchase Agreement with certain institutional and other accredited investors, whereby it, in a private placement, agreed to issue and sell to the investors an aggregate of 6,585,000 shares of the Company’s common stock, $0.001 par value per share, at a price of $2.05 per share and 5,610,121 shares of the Company’s Series B Convertible Preferred Stock, $0.001 par value per share which are convertible into shares of the Company’s Common Stock, at a price of $2.05 per share. The Series B Preferred Stock, which is a Common Stock equivalent but non-voting and with a blocker on conversion if the holder would exceed a specified threshold of voting security ownership, is convertible into Common Stock on a one-for-one basis, subject to adjustment for events such as stock splits, combinations and the like as provided in the Purchase Agreement. The Series B Convertible Preferred Stock is reported in the stockholders’ equity section of the Company’s balance sheet. The Company received net proceeds of approximately $23.1 million, after offering expenses.

Series A Convertible Preferred Stock and Warrants

In September 2016, the Company issued 24,000 shares of Series A Convertible Preferred Stock, par value $0.001 with a stated value of $1,000 per share which are convertible into shares of the Company’s common stock at an initial conversion rate of $0.65 per share and (ii) warrants to purchase an aggregate of 36,923,078 shares of common stock. The convertible preferred shares are entitled to vote on an as-converted basis with the common stock, subject to specified beneficial ownership issuance limitations. The convertible preferred shares bear dividends at a rate of six percent (6%) per annum, which are cumulative and accrue daily from the date of issuance on the $1,000 stated value. Such dividends will not be paid in cash except in connection with any liquidation, dissolution or winding up of the Company or any redemption of the convertible preferred shares. Each holder of convertible preferred shares has the right to require us to redeem such holder’s convertible preferred shares upon the occurrence of specified events, which include certain business combinations, the sale of all or substantially all of the Company’s assets, or the sale of more than 50% of the outstanding shares of the Company’s common stock. In addition, the Company has the right to redeem the convertible preferred shares in the event of a defined change of control. The convertible preferred shares rank senior to our common stock as to distributions and payments upon the liquidation, dissolution, and winding up of the Company. Since the convertible preferred shares are subject to conditions for redemption that are outside the Company’s control, the convertible preferred shares are presently reported in the mezzanine section of the balance sheet.

The warrants issued in conjunction with the convertible preferred stock (the “SPA Warrants”) have an exercise price equal to $0.70 per share subject to adjustments as provided under the terms of the warrants. The warrants are exercisable through September 29, 2021, subject to specified beneficial ownership issuance limitations.

Stock Award Plans

The Company has various stock plans that permit the Company to provide incentives to employees and directors of the Company in the form of equity compensation. In July 2012, the Compensation Committee of the Board of Directors adopted the 2012 Stock Incentive Plan (the “Plan”) which was subsequently approved by the Company’s shareholders. This plan replaced the 2002 Stock Incentive Plan which expired on March 25, 2012.

At June 30, 2020, the Company had 2,233,242 remaining shares of the Company’s common stock to provide for current and future grants under its various equity plans.

At June 30, 2020, the total compensation cost related to options, stock appreciation rights, and non-vested stock granted to employees under the Company’s stock award plans but not yet recognized was approximately $3.9 million. This cost will be amortized over a period of up to four years over the underlying estimated service periods and will be adjusted for subsequent changes in actual forfeitures and anticipated vesting periods.

A summary of the option and stock appreciation rights activity for the six month period ended June 30, 2020 is as follows:

	Number of Options/SARs			Range of Exercise Price		Weighted Average Exercise Price per Share
Outstanding, December 31, 2019		1,857,599		$	0.74 - $36.20	$	2.22
Granted		897,250		$	3.98 - $5.13	$	4.52
Exercised		(80,785	)	$	0.74 - $2.03	$	1.22
Forfeited		(137,164	)	$	0.74 - $36.20	$	5.86
Outstanding, June 30, 2020		2,536,900		$	0.74 - $35.20	$	2.87

A summary of the restricted stock unit activity for the six month period ended June 30, 2020 is as follows:

	Number of Restricted Stock Units			Weighted Average Grant Date Fair Value per Unit
Outstanding, December 31, 2019		840,712		$	1.28
Granted		210,000		$	5.24
Vested		(116,989	)	$	1.96
Forfeited		(250	)	$	0.78
Outstanding, June 30, 2020		933,473		$	2.08

Product Warranty Provisions

6 Months Ended

Jun. 30, 2020

Guarantees and Product Warranties [Abstract]

Product Warranty Provisions

10. Product Warranty Provisions

The Company’s standard policy is to warrant all capital systems against defects in material or workmanship for one year following installation. The Company’s estimate of costs to service the warranty obligations is based on historical experience and current product performance trends. A regular review of warranty obligations is performed to determine the adequacy of the reserve and adjustments are made to the estimated warranty liability as appropriate.

Accrued warranty, which is included in other accrued liabilities, consists of the following:

Schedule of Accrued Warranty

	June 30, 2020			December 31, 2019
Warranty accrual, beginning of the fiscal period	$	141,697		$	149,464
Accrual adjustment for product warranty		12,287			56,118
Payments made		(26,279	)		(63,885	)
Warranty accrual, end of the fiscal period	$	127,705		$	141,697

Commitments and Contingencies

6 Months Ended

Jun. 30, 2020

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

11. Commitments and Contingencies

The Company at times becomes a party to claims in the ordinary course of business. Management believes that the ultimate resolution of pending or threatened proceedings will not have a material effect on the financial position, results of operations or liquidity of the Company.

Subsequent Events

6 Months Ended

Jun. 30, 2020

Subsequent Events [Abstract]

Subsequent Events

12. Subsequent Events

None.

Summary of Significant Accounting Policies (Policies)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Risks and Uncertainties

Risks and Uncertainties

Financial Instruments

Financial Instruments

Revenue and Costs of Revenue

Revenue and Costs of Revenue

The Company accounts for revenue in accordance with Accounting Standards Codification Topic 606 (“ASC 606”), Revenue from Contracts with Customers.

Systems:

Disposables:

Royalty:

Other Recurring Revenue:

Sublease Revenue:

	Three Months Ended June 30				Six Months Ended June 30,
	2020		2019		2020		2019
Systems	$	12,769	$	-	$	12,769	$	58,051
Disposables, service and accessories		5,086,156		6,546,115		10,595,867		13,256,873
Sublease		246,530		251,996		493,060		493,061
Total revenue	$	5,345,455	$	6,798,111	$	11,101,696	$	13,807,985

The following information summarizes the Company’s contract assets and liabilities:

	June 30, 2020			December 31, 2019
Contract Assets - Unbilled Receivables	$	244,304		$	168,445

Customer deposits		597,000			-
Product shipped, revenue deferred		645,200			674,324
Deferred service and license fees		4,723,167			4,972,389
Total deferred revenue		5,965,367			5,646,713
Less: Long-term deferred revenue		(508,772	)		(554,258	)
Total current deferred revenue	$	5,456,595		$	5,092,455

Assets Recognized from the Costs to Obtain a Contract with a Customer

Assets Recognized from the Costs to Obtain a Contract with a Customer

Share-Based Compensation

Share-Based Compensation

Net Earnings (Loss) per Common Share

Net Earnings (Loss) per Common Share

The following table sets forth the computation of basic and diluted EPS:

	2020			2019			2020			2019
	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Net loss	$	(1,921,106	)	$	(1,427,718	)	$	(3,892,637	)	$	(3,550,538	)
Cumulative dividend on convertible preferred stock		(342,126	)		(357,194	)		(685,849	)		(710,704	)
Net loss attributable to common stockholders	$	(2,263,232	)	$	(1,784,912	)	$	(4,578,486	)	$	(4,261,242	)

Weighted average number of common shares and equivalents:		71,628,762			60,052,673			70,749,401			59,936,606
Basic EPS	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.07	)
Diluted EPS	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.07	)

Recently Issued Accounting Pronouncements

Recently Issued Accounting Pronouncements

Summary of Significant Accounting Policies (Tables)

6 Months Ended

Jun. 30, 2020

Accounting Policies [Abstract]

Schedule of Revenue Disaggregated by Type

	Three Months Ended June 30				Six Months Ended June 30,
	2020		2019		2020		2019
Systems	$	12,769	$	-	$	12,769	$	58,051
Disposables, service and accessories		5,086,156		6,546,115		10,595,867		13,256,873
Sublease		246,530		251,996		493,060		493,061
Total revenue	$	5,345,455	$	6,798,111	$	11,101,696	$	13,807,985

Summary of Contract Assets and Liabilities

The following information summarizes the Company’s contract assets and liabilities:

	June 30, 2020			December 31, 2019
Contract Assets - Unbilled Receivables	$	244,304		$	168,445

Customer deposits		597,000			-
Product shipped, revenue deferred		645,200			674,324
Deferred service and license fees		4,723,167			4,972,389
Total deferred revenue		5,965,367			5,646,713
Less: Long-term deferred revenue		(508,772	)		(554,258	)
Total current deferred revenue	$	5,456,595		$	5,092,455

Schedule of Computation of Basic and Diluted Earnings Per Share

The following table sets forth the computation of basic and diluted EPS:

	2020			2019			2020			2019
	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Net loss	$	(1,921,106	)	$	(1,427,718	)	$	(3,892,637	)	$	(3,550,538	)
Cumulative dividend on convertible preferred stock		(342,126	)		(357,194	)		(685,849	)		(710,704	)
Net loss attributable to common stockholders	$	(2,263,232	)	$	(1,784,912	)	$	(4,578,486	)	$	(4,261,242	)

Weighted average number of common shares and equivalents:		71,628,762			60,052,673			70,749,401			59,936,606
Basic EPS	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.07	)
Diluted EPS	$	(0.03	)	$	(0.03	)	$	(0.06	)	$	(0.07	)

Inventories (Tables)

6 Months Ended

Jun. 30, 2020

Inventory Disclosure [Abstract]

Schedule of Inventories

Inventories consist of the following:

	June 30, 2020			December 31, 2019
Raw materials	$	4,938,417		$	3,063,532
Work in process		563,838			515,262
Finished goods		2,988,008			2,164,187
Reserve for obsolescence		(3,914,185	)		(3,895,451	)
Total inventory	$	4,576,078		$	1,847,530

Prepaid Expenses and Other Assets (Tables)

6 Months Ended

Jun. 30, 2020

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

Schedule of Prepaid Expenses and Other Assets

Prepaid expenses and other assets consist of the following:

	June 30, 2020			December 31, 2019
Prepaid expenses	$	831,103		$	640,252
Prepaid commissions		294,518			336,594
Deposits		665,308			712,179
Other assets		90,117			-
Total prepaid expenses and other assets		1,881,046			1,689,025
Less: Noncurrent prepaid expenses and other assets		(269,542	)		(218,103	)
Total current prepaid expenses and other assets	$	1,611,504		$	1,470,922

Property and Equipment (Tables)

6 Months Ended

Jun. 30, 2020

Property, Plant and Equipment [Abstract]

Schedule of Property and Equipment

	June 30, 2020			December 31, 2019
Equipment	$	6,556,769		$	6,485,873
Leasehold improvements		2,338,441			2,338,441
		8,895,210			8,824,314
Less: Accumulated depreciation		(8,632,171	)		(8,573,871	)
Net property and equipment	$	263,039		$	250,443

Leases (Tables)

6 Months Ended

Jun. 30, 2020

Leases [Abstract]

Schedule of Lease Costs and Other Lease Information

The following table represents lease costs and other lease information.

	2020			2019			2020			2019
	Three Months Ended June 30,						Six Months Ended June 30,
	2020			2019			2020			2019
Operating lease cost	$	585,584		$	585,585		$	1,171,170		$	1,171,171
Short-term lease cost		19,304			18,831			34,774			38,639
Sublease income		(246,530	)		(251,996	)		(493,060	)		(493,061	)
Total lease cost	$	358,358		$	352,420		$	712,884		$	716,749

Cash paid within operating cash flows	$	588,897		$	612,224		$	1,225,247		$	1,227,490

Schedule of Future Minimum Operating Lease Payments

Future minimum payments for operating leases with initial or remaining terms of one year or more as of June 30, 2020, excluding sublease income, were as follows:

	June 30, 2020
2020	$	1,168,947
2021		2,382,661
Total lease payments		3,551,608
Less: Interest		(216,972	)
Present value of lease liabilities	$	3,334,636

Accrued Liabilities (Tables)

6 Months Ended

Jun. 30, 2020

Payables and Accruals [Abstract]

Schedule of Accrued Liabilities

Accrued liabilities consist of the following:

Schedule of Accrued Liabilities

	June 30, 2020			December 31, 2019
Accrued salaries, bonus, and benefits	$	1,311,427		$	1,421,150
Accrued licenses and maintenance fees		483,879			483,879
Accrued warranties		127,705			141,697
Accrued taxes		200,041			206,232
Accrued professional services		206,903			383,342
Other		327,187			340,321
Total accrued liabilities		2,657,142			2,976,621
Less: Long term accrued liabilities		(255,517	)		(255,517	)
Total current accrued liabilities	$	2,401,625		$	2,721,104

Convertible Preferred Stock and Stockholders’ Equity (Tables)

6 Months Ended

Jun. 30, 2020

Equity [Abstract]

Summary of Option and Stock Appreciation Rights Activity

A summary of the option and stock appreciation rights activity for the six month period ended June 30, 2020 is as follows:

	Number of Options/SARs			Range of Exercise Price		Weighted Average Exercise Price per Share
Outstanding, December 31, 2019		1,857,599		$	0.74 - $36.20	$	2.22
Granted		897,250		$	3.98 - $5.13	$	4.52
Exercised		(80,785	)	$	0.74 - $2.03	$	1.22
Forfeited		(137,164	)	$	0.74 - $36.20	$	5.86
Outstanding, June 30, 2020		2,536,900		$	0.74 - $35.20	$	2.87

Summary of Restricted Stock Unit Activity

A summary of the restricted stock unit activity for the six month period ended June 30, 2020 is as follows:

	Number of Restricted Stock Units			Weighted Average Grant Date Fair Value per Unit
Outstanding, December 31, 2019		840,712		$	1.28
Granted		210,000		$	5.24
Vested		(116,989	)	$	1.96
Forfeited		(250	)	$	0.78
Outstanding, June 30, 2020		933,473		$	2.08

Product Warranty Provisions (Tables)

6 Months Ended

Jun. 30, 2020

Guarantees and Product Warranties [Abstract]

Schedule of Accrued Warranty

Accrued warranty, which is included in other accrued liabilities, consists of the following:

Schedule of Accrued Warranty

	June 30, 2020			December 31, 2019
Warranty accrual, beginning of the fiscal period	$	141,697		$	149,464
Accrual adjustment for product warranty		12,287			56,118
Payments made		(26,279	)		(63,885	)
Warranty accrual, end of the fiscal period	$	127,705		$	141,697

Description of Business (Details Narrative)	Jun. 30, 2020 Integer
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Installed base	123

Schedule of Revenue Disaggregated by Type (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Product Information [Line Items]
Total revenue	$ 5,345,455	$ 6,798,111	$ 11,101,696	$ 13,807,985
Sublease	246,530	251,996	493,060	493,061
Systems [Member]
Product Information [Line Items]
Total revenue	12,769	(0)	12,769	58,051
Disposables, Service and Accessories [Member]
Product Information [Line Items]
Total revenue	$ 5,086,156	$ 6,546,115	$ 10,595,867	$ 13,256,873

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Summary of Contract Assets and Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Product Information [Line Items]
Total deferred revenue	$ 5,965,367	$ 5,646,713
Less: Long-term deferred revenue	(508,772)	(554,258)
Total current deferred revenue	5,456,595	5,092,455
Contract Assets - Unbilled Receivables [Member]
Product Information [Line Items]
Total deferred revenue	244,304	168,445
Customer Deposits [Member]
Product Information [Line Items]
Total deferred revenue	597,000	(0)
Product Shipped, Revenue Deferred [Member]
Product Information [Line Items]
Total deferred revenue	645,200	674,324
Deferred Service and License Fees [Member]
Product Information [Line Items]
Total deferred revenue	$ 4,723,167	$ 4,972,389

Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Accounting Policies [Abstract]
Net loss	$ (1,921,106)	$ (1,427,718)	$ (3,892,637)	$ (3,550,538)
Cumulative dividend on convertible preferred stock	(342,126)	(357,194)	(685,849)	(710,704)
Net loss attributable to common stockholders	$ (2,263,232)	$ (1,784,912)	$ (4,578,486)	$ (4,261,242)
Weighted average number of common shares and equivalents:	71,628,762	60,052,673	70,749,401	59,936,606
Basic EPS	$ (0.03)	$ (0.03)	$ (0.06)	$ (0.07)
Diluted EPS	$ (0.03)	$ (0.03)	$ (0.06)	$ (0.07)

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794

+ Details

- Definition

Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=121326447&loc=d3e1377-109256

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 10: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

+ Details

Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ / shares in Units, $ in Millions	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2019
Product Information [Line Items]
Remaining performance obligation	$ 4.2
Revenue recognized	4.0	$ 4.3
Capitalized contract acquisition costs	$ 0.3		$ 0.3
Share-based compensation, requisite service period	four years
Weighted average exercise price	$ 2.87		$ 2.22
Exercise price of warrants	$ 0.70
Series A Convertible Preferred Stock [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	43,000,941
Series B Convertible Preferred Stock [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	5,610,121
Warrant [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	15,385
Exercise price of warrants	$ 0.70
Stock Optionsand Stock Appreciation Rights [Member]
Product Information [Line Items]
Potential common shares excluded from diluted earnings per share	2,536,900
Weighted average exercise price	$ 2.87
Restricted Stock [Member]
Product Information [Line Items]
Number of unvested restricted share units	933,473
Revenue from System Delivery and Installation [Member] \| Maximum [Member]
Product Information [Line Items]
Revenues percentage	1.00%	1.00%
Disposable Revenue [Member]
Product Information [Line Items]
Revenues percentage	31.00%	36.00%
Royalty Revenue [Member]
Product Information [Line Items]
Revenues percentage	9.00%	10.00%
Other Recurring Revenue [Member]
Product Information [Line Items]
Revenues percentage	56.00%	50.00%
Sublease Revenue [Member]
Product Information [Line Items]
Revenues percentage	4.00%	4.00%

Schedule of Inventories (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Inventory Disclosure [Abstract]
Raw materials	$ 4,938,417	$ 3,063,532
Work in process	563,838	515,262
Finished goods	2,988,008	2,164,187
Reserve for obsolescence	(3,914,185)	(3,895,451)
Total inventory	$ 4,576,078	$ 1,847,530

Schedule of Prepaid Expenses and Other Assets (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid expenses	$ 831,103	$ 640,252
Prepaid commissions	294,518	336,594
Deposits	665,308	712,179
Other assets	90,117
Total prepaid expenses and other assets	1,881,046	1,689,025
Less: Noncurrent prepaid expenses and other assets	(269,542)	(218,103)
Total current prepaid expenses and other assets	$ 1,611,504	$ 1,470,922

Schedule of Property and Equipment (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 8,895,210	$ 8,824,314
Less: Accumulated depreciation	(8,632,171)	(8,573,871)
Net property and equipment	263,039	250,443
Equipment [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	6,556,769	6,485,873
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Gross property and equipment	$ 2,338,441	$ 2,338,441

Schedule of Lease Costs and Other Lease Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Leases [Abstract]
Operating lease cost	$ 585,584	$ 585,585	$ 1,171,170	$ 1,171,171
Short-term lease cost	19,304	18,831	34,774	38,639
Sublease income	(246,530)	(251,996)	(493,060)	(493,061)
Total lease cost	358,358	352,420	712,884	716,749
Cash paid within operating cash flows	$ 588,897	$ 612,224	$ 1,225,247	$ 1,227,490

Schedule of Future Minimum Operating Lease Payments (Details)	Jun. 30, 2020 USD ($)
Leases [Abstract]
2020	$ 1,168,947
2021	2,382,661
Total lease payments	3,551,608
Less: Interest	(216,972)
Present value of lease liabilities	$ 3,334,636

Leases (Details Narrative) - USD ($)	Jun. 30, 2020	Dec. 31, 2019	Jan. 02, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Weighted average discount rate for operating leases	9.00%
Weighted average remaining lease term for operating lease term	1 year 6 months
Right of use assets	$ 3,282,783	$ 4,286,064
Undiscounted future cash flows to be received under the sublease 2020	500,000
Undiscounted future cash flows to be received under the sublease 2021	$ 1,000,000.0
Accounting Standards Update 2016-02 [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Right of use assets			$ 6,200,000

Schedule of Accrued Liabilities (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued salaries, bonus, and benefits	$ 1,311,427	$ 1,421,150
Accrued licenses and maintenance fees	483,879	483,879
Accrued warranties	127,705	141,697
Accrued taxes	200,041	206,232
Accrued professional services	206,903	383,342
Other	327,187	340,321
Total accrued liabilities	2,657,142	2,976,621
Less: Long term accrued liabilities	(255,517)	(255,517)
Total current accrued liabilities	$ 2,401,625	$ 2,721,104

Debt and Credit Facilities (Details Narrative) - USD ($)		6 Months Ended
	Apr. 20, 2020	Jun. 30, 2020	Jun. 30, 2019
Line of Credit Facility [Line Items]
Proceeds from Bank Debt		$ 2,158,310
CARES Act [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Description	In accordance with the loan forgiveness requirements of the CARES Act, the Company intends to use the proceeds from the PPP Loan primarily for payroll costs, rent and utilities.
Paycheck Protection Program [Member]
Line of Credit Facility [Line Items]
Proceeds from Bank Debt	$ 2,158,310
Debt Instrument, Interest Rate, Stated Percentage	1.00%
Revolving Credit Facility [Member] \| Primary Lender [Member]
Line of Credit Facility [Line Items]
Line of credit maturity date		Jun. 30, 2020

- Definition

Identification of the lender and information about a contractual promise to repay a short-term or long-term obligation, which includes borrowings under lines of credit, notes payable, commercial paper, bonds payable, debentures, and other contractual obligations for payment. This may include rationale for entering into the arrangement, significant terms of the arrangement, which may include amount, repayment terms, priority, collateral required, debt covenants, borrowing capacity, call features, participation rights, conversion provisions, sinking-fund requirements, voting rights, basis for conversion if convertible and remarketing provisions. The description may be provided for individual debt instruments, rational groupings of debt instruments, or by debt in total.

+ References + Details

Summary of Option and Stock Appreciation Rights Activity (Details)	6 Months Ended
	Jun. 30, 2020 $ / shares shares
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options/SARs, Outstanding, Beginning Balance \| shares	1,857,599
Weighted Average Exercise Price per Share, Outstanding, Beginning Balance	$ 2.22
Number of Options/SARs, Granted \| shares	897,250
Weighted Average Exercise Price per Share, Granted	$ 4.52
Number of Options/SARs, Exercised \| shares	(80,785)
Weighted Average Exercise Price per Share, Exercised	$ 1.22
Number of Options/SARs, Forfeited \| shares	(137,164)
Weighted Average Exercise Price per Share, Forfeited	$ 5.86
Number of Options/SARs, Outstanding, Ending Balance \| shares	2,536,900
Weighted Average Exercise Price per Share, Outstanding, Ending Balance	$ 2.87
Range One [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	36.20
Range Two [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	3.98
Range of Exercise Price, Upper Limit	5.13
Range Three [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	2.03
Range Four [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	36.20
Range Five [Member]
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Range of Exercise Price, Lower Limit	0.74
Range of Exercise Price, Upper Limit	$ 35.20

Summary of Restricted Stock Unit Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended
	Jun. 30, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Restricted Stock Units, Outstanding, Ending	933,473	840,712
Weighted Average Grant Date Fair Value Per Unit, Outstanding, Ending	$ 2.08	$ 1.28
Number of Restricted Stock Units, Granted	210,000
Weighted Average Grant Date Fair Value Per Unit, Granted	$ 5.24
Number of Restricted Stock Units, Vested	(116,989)
Weighted Average Grant Date Fair Value Per Unit, Vested	$ 1.96
Number of Restricted Stock Units, Forfeited	(250)
Weighted Average Grant Date Fair Value Per Unit, Forfeited	$ 0.78

Convertible Preferred Stock and Stockholders’ Equity (Details Narrative) - USD ($)			1 Months Ended	6 Months Ended
	May 25, 2020	Aug. 07, 2019	Sep. 30, 2016	Jun. 30, 2020	Dec. 31, 2019
Subsidiary, Sale of Stock [Line Items]
Number of stockholders votes, description				one
Dividends declared				$ 0
Dividends paid				$ 0
Common stock, par value				$ 0.001	$ 0.001
Preferred stock, par or stated value				0.001	$ 0.001
Exercise price of warrants				$ 0.70
Warrants exercisable date				Sep. 29, 2021
Remaining shares available for issuance				2,233,242
Total compensation cost not yet recognized				$ 3,900,000
Weighted average amortization period of total compensation cost not yet recognized, description				four years
Series A Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Preferred stock, par or stated value			$ 1,000
Number of preferred stock issued			24,000
Preferred stock, par value			$ 0.001
Preferred stock, conversion price			$ 0.65
Common stock issuable from warrants			36,923,078
Preferred stock dividend rate			6.00%
Preferred stock redemption, triggering event, percent of common stock sold threshold			50.00%
Direct Registered Offering [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds received	$ 15,000,000.0
Direct Registered Offering [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares sold	3,658,537
Common stock, par value	$ 0.001
Sale of stock, price per share	$ 4.10
Private Placement [Member]
Subsidiary, Sale of Stock [Line Items]
Net proceeds received		$ 23,100,000
Private Placement [Member] \| Common Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares sold		6,585,000
Common stock, par value		$ 0.001
Sale of stock, price per share		$ 2.05
Private Placement [Member] \| Series B Convertible Preferred Stock [Member]
Subsidiary, Sale of Stock [Line Items]
Sale of stock, number of shares sold		5,610,121
Preferred stock, par or stated value		$ 0.001
Conversion price per share		$ 2.05

Schedule of Accrued Warranty (Details) - USD ($)	6 Months Ended	12 Months Ended
Schedule of Accrued Warranty (Details) - USD ($)	Jun. 30, 2020	Dec. 31, 2019
Guarantees and Product Warranties [Abstract]
Warranty accrual, beginning of the fiscal period	$ 141,697	$ 149,464
Accrual adjustment for product warranty	12,287	56,118
Payments made	(26,279)	(63,885)
Warranty accrual, end of the fiscal period	$ 127,705	$ 141,697

Product Warranty Provisions (Details Narrative)	6 Months Ended
Product Warranty Provisions (Details Narrative)	Jun. 30, 2020
Guarantees and Product Warranties [Abstract]
Standard product warranty coverage term	one year